Modular, Single-Use Facilities Increase Biomanufacturing Flexibility
Source: Sartorius

The pipelines of biopharmaceutical companies are becoming increasingly diverse while improvements in cell lines are leading to more productive bioprocesses. These factors are driving new capacity demands for biopharmaceutical companies and their CDMO partners. It is becoming increasingly important, therefore, that companies implement Innovative, highly efficient, flexible facilities that are capable of meeting these challenging capacity demands.
New Biomanufacturing Facilities must meet the following requirements
- Apply single-use technologies for lower capital expenditures (CAPEX), from cell vial to drug product vial and from development to routine manufacturing
- Provide a platform for rapid transition between product development and commercialization
- Ensure rapid start-up and ease of compliance – Be reusable and flexible as process and products change (New manufacturing strategies)
- Allow process transfers readily
- Allow the development of automation and control strategies, including PAT, data analysis, real-time release
- Allow security of supply (single-source vs. multiple sourcing)
VIEW THE POSTER!
Log In
Signing up provides unlimited access to:
Free Sign Up

Signing up provides unlimited access to:
- Trend and Leadership Articles
- Case Studies
- Extensive Product Database
- Premium Content
HELLO. PLEASE LOG IN.
X
Not yet a member of Pharmaceutical Online? Register today.
ACCOUNT SIGN UP
X
Please fill in your account details
ACCOUNT SIGN UP
Sartorius
This website uses cookies to ensure you get the best experience on our website. Learn more